Drug Trial Radar · NCT04960709
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
Last checked: Nov 20, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
712
Actual
Start
Aug 5, 2021
Primary completion
Mar 2, 2026
Study completion Sep 8, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jul 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A global phase 3, multicenter, randomized, trial, to Determine the Efficacy and Safety of Durvalumab in combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in combination with Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or who refuse Cisplatin based chemotherapy Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer. The goal of the study is to explore the triplet combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or the duplet combination of Durvalumab and Enfortumab vedotin in terms of efficacy and safety compared to the current Standard Of Care (SOC). VOLGA trial consists of two parts: Safety Run-In and Main Study. In total the study aims to enroll approximately 677 patients, who will receive triplet combination, duplet combination or currently approved SOC in the main study. In the main part of the trial there is two out of three chances of being on a treatment arm and the treatment is assigned at random by a computer system. In this trial patients in the two treatment arms will receive either 3 cycles of neoadjuvant Durvalumab + Enfortumab Vedotin and 2 cycles of Tremelimumab or Durvalumab + Enfortumab vedotin and after surgery both treatment arms will receive either adjuvant Durvalumab or adjuvant Durvalumab and 1 cycle of Tremelimumab.
Conditions
- Muscle Invasive Bladder Cancer
Interventions
DurvalumabDrug
Anti- PD-L1 Antibody
TremelimumabDrug
Human IgG2 mAb
Enfortumab VedotinDrug
Nectin-4-directed antibody and microtubule inhibitor conjugate
Radical CystectomyProcedure
For cisplatin-ineligible or cisplatin-refusal patients
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the safety and tolerability as evaluated by adverse events occurring throughout the study (Safety Run-In part)Time frame: At completion of study treatment by the last patient and at 3 months.
- To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by vital signs (blood pressure in mmHg) (Safety Run-In part)Time frame: Up to 84 months
- To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by vital signs (pulse rate) in beats per minute (Safety Run-In part)Time frame: Up to 84 months
- To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by vital signs (respiration rate) in breaths per minute (Safety Run-In part)Time frame: Up to 84 months
- To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by vital signs (temperature) in degrees Celsius (Safety Run-In part)Time frame: Up to 84 months
- To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by abnormality in clinical chemistry by liver function (Safety Run-In part)Time frame: Up to 84 months
- Safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin or who refuse cisplatin as assessed by abnormality in clinical chemistry by kidney function (Safety Run-In part)Time frame: Up to 84 months
- To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by abnormality in clinical chemistry by thyroid function (Safety Run-In part)Time frame: Up to 84 months
- To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by abnormality in haematology (Safety Run-In part)Time frame: Up to 84 months
- To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as as assessed by ECG (pulse rate) (Safety Run-In part)Time frame: Up to 84 months
- Changes in WHO/ECOG performance status (Safety Run-In part)Time frame: Up to 84 months
- Compare efficacy of durvalumab + tremelimumab + EV (Arm 1) relative to cystectomy (Arm 3) and durvalumab + EV (Arm 2) relative to cystectomy (Arm 3) on EFS (Main Study)Time frame: Up to 3 years
Locations
196 sites in 25 countries. Site status is shown where the registry gives one.
Research Site
Orange, California
Research Site
Santa Monica, California
Research Site
New Haven, Connecticut
Research Site
Washington D.C., District of Columbia
Research Site
Fort Myers, Florida
Research Site
Coeur d'Alene, Idaho
Research Site
Maywood, Illinois
Research Site
Indianapolis, Indiana
Research Site
Iowa City, Iowa
Research Site
Louisville, Kentucky
Research Site
Scarborough, Maine
Research Site
Boston, Massachusetts
Research Site
Brighton, Michigan
Research Site
Jackson, Mississippi
Research Site
Las Vegas, Nevada
Research Site
Saddle Brook, New Jersey
Research Site
Brooklyn, New York
Research Site
Buffalo, New York
Research Site
New York, New York
Research Site
Syracuse, New York
Research Site
Portland, Oregon
Research Site
Hershey, Pennsylvania
Research Site
Pittsburgh, Pennsylvania
Research Site
Knoxville, Tennessee
Research Site
Austin, Texas
Research Site
Dallas, Texas
Research Site
Fort Worth, Texas
Research Site
Houston, Texas
Research Site
Irving, Texas
Research Site
Norfolk, Virginia
Research Site
Spokane, Washington
Research Site
Buenos Aires, Argentina
Research Site
CABA, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Pergamino, Argentina
Research Site
Graz, Austria
Research Site
Krems, Austria
Research Site
Linz, Austria
Research Site
Vienna, Austria
Showing 40 of 196 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.